Interleukin-6 Receptor Antagonists in Critically Ill Patients with Covid-19 – Preliminary reportChristopher W. Seymour, Michelle A. Detry, Eamon Duffy et al.|medRxiv|2021Cited by 137
Lopinavir-ritonavir and hydroxychloroquine for critically ill patients with COVID-19: REMAP-CAP randomized controlled trialYaseen M. Arabi, Anthony Gordon, Lennie Derde et al.|Intensive Care Medicine|2021Cited by 100
Effectiveness of Casirivimab-Imdevimab and Sotrovimab During a SARS-CoV-2 Delta Variant SurgeDavid T. Huang, Christopher Seymour, Erin K McCreary et al.|JAMA Network Open|2022Cited by 54
Association of Subcutaneous or Intravenous Administration of Casirivimab and Imdevimab Monoclonal Antibodies With Clinical Outcomes in Adults With COVID-19Erin K McCreary, Kevin E. Kip, J Ryan Bariola et al.|JAMA Network Open|2022Cited by 36
The comparative effectiveness of COVID-19 monoclonal antibodies: A learning health system randomized clinical trialErin K McCreary, David T. Huang, J Ryan Bariola et al.|Contemporary Clinical Trials|2022Cited by 26